An empirical approach to signature peptide choice for selected reaction monitoring: Quantification of uromodulin in urine

Clinical Chemistry

Volumn 62, Issue 1, 2016, Pages 198-207

  Fu, Qin ^a   Grote, Eric ^b   Zhu, Jie ^b   Jelinek, Christine ^b   Köttgen, Anna ^c,d   Coresh, Josef ^c   Van Eyk, Jennifer E ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; TAMM HORSFALL GLYCOPROTEIN; BIOLOGICAL MARKER;

ARTICLE; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STANDARD; TANDEM MASS SPECTROMETRY; URINALYSIS; AMINO ACID SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MASS SPECTROMETRY; MOLECULAR GENETICS; NORMAL HUMAN; URINE;

AMINO ACID SEQUENCE; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEALTHY VOLUNTEERS; HUMANS; MALE; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; UROMODULIN;

EID: 84954484400     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.242495     Document Type: Article

References (28)

1. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
2. Kuzyk MA, Parker CE, Domanski D, Borchers CH. Development of MRM-based assays for the absolute quantitation of plasma proteins. Methods Mol Biol 2013;1023:53-82.
3. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009;3:33-44.
4. Yassine HN, Jackson AM, Borges CR, Billheimer D, Koh H, Smith D, et al. The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins. Lipids Health Dis 2014;13:8.
5. Grote E, Fu Q, Ji W, Liu X, Van Eyk JE. Using pure protein to build a multiple reaction monitoring mass spectrometry assay for targeted detection and quantitation. Methods Mol Biol 2013;1005:199-213.
6. Rampoldi L, Kottgen A, Devuyst O. The effect ofcommon uromodulin variants on urinary protein level and gene transcription. Kidney Int 2013;84:410-1.
7. Graham LA, Padmanabhan S, Fraser NJ, Kumar S, Bates JM, Raffi HS, et al. Validation of uromodulin as a candidate gene for human essential hypertension. Hypertension 2014;63:551-8.
8. Bleyer AJ, Hart TC. Medullary cystic kidney disease type 2. Am J Kidney Dis 2004;43:1142; author reply 1143.
9. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 2011;80:338-47.
10. Kottgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009;41:712-7.
11. Gudbjartsson DF, Holm H, Indridason OS, Thorleifsson G, Edvardsson V, Sulem P, et al. Association of variants at UMOD with chronic kidney disease and kidney stones: role of age and comorbid diseases. PLoS genetics 2010;6:e1001039.
12. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, et al. Genome-wide association study of blood pressure extremes identifies variant near umod associated with hypertension. PLoS genetics 2010;6:e1001177.
13. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, et al. Common noncodingUMODgene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med 2013;19:1655-60.
14. Thongboonkerd V. Practical points in urinary proteomics. J Proteome Res 2007;6:3881-90.
15. Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry 2013;52:3797-806.
16. Bereman MS, MacLean B, Tomazela DM, Liebler DC, MacCoss MJ. The development of selected reaction monitoring methods for targeted proteomics via empirical refinement. Proteomics 2012;12:1134-41.
17. Chang CY, Picotti P, Huttenhain R, Heinzelmann-Schwarz V, Jovanovic M, Aebersold R, Vitek O. Protein significance analysis in selected reaction monitoring (SRM) measurements. Mol Cell Proteomics 2012;11:M111 014662.
18. Farrah T, Deutsch EW, Kreisberg R, Sun Z, Campbell DS, Mendoza L, et al. Passel: The PeptideAtlas SRMexperiment library. Proteomics 2012;12:1170-5.
19. Kusebauch U, Deutsch EW, Campbell DS, Sun Z, Farrah T, Moritz RL. Using PeptideAtlas, SRMatlas, and PASSEL: comprehensive resources for discovery and targeted proteomics. Curr Protocols Bioinformat 2014;46:13.25.1-8.
20. Webb-Robertson BJ, Cannon WR, Oehmen CS, Shah AR, Gurumoorthi V, Lipton MS, Waters KM. A support vector machine model for the prediction of proteotypic peptides for accurate mass and time proteomics. Bioinformatics 2010;26:1677-83.
21. Liu X, Jin Z, O'Brien R, Bathon J, Dietz HC, Grote E, Van Eyk JE. Constrained selected reaction monitoring: quantification of selected posttranslational modifications and protein isoforms. Methods 2013;61:304-12.
22. Percy AJ, Chambers AG, Parker CE, Borchers CH. Absolute quantitation of proteins in human blood by multiplexed multiple reaction monitoring mass spectrometry. Methods Mol Biol 2013;1000:167-89.
23. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687-702.
24. Kottgen A, Hwang SJ, Larson MG, Van Eyk JE, Fu Q, Benjamin EJ, et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010;21:337-44.
25. Grant RP, Hoofnagle AN. From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry. Clin Chem 2014;60:941-4.
26. Shuford CM, Sederoff RR, Chiang VL, Muddiman DC. Peptide production and decay rates affect the quantitative accuracy of protein cleavage isotope dilution mass spectrometry (PC-IDMS). Mol Cell Proteomics 2012;11:814-23.
27. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin Appl 2010;4:271-84.
28. Prabakaran M, Ho HT, Prabhu N, Velumani S, Szyporta M, He F, et al. Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS ONE 2009;4:e4566.